Trials / Unknown
UnknownNCT04966975
Effect and Prognosis of Immunohistochemical Biomarkers Changes in Patients With Bladder Cancer After Neoadjuvant Chemotherapy
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 60 (estimated)
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Clinical trial to investigate the relationship between the expression of immunohistochemical biomarkers GATA-3, CK20, P53 and Ki67 in bladder cancer and pathological complete response after neoadjuvant chemotherapy.
Detailed description
This is a retrospective study included bladder cancer patients treated with neoadjuvant chemotherapy. We analyzed the changes in the expression of GATA-3, CK20, P53 and Ki67 before and after NAC. Evaluating the sensitivity factor for predicting pathological complete response.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | neoadjuvant chemotherapy | The patients receive neoadjuvant chemotherapy for 2-4 cycles before surgery. |
Timeline
- Start date
- 2021-09-01
- Primary completion
- 2022-08-31
- Completion
- 2022-08-31
- First posted
- 2021-07-19
- Last updated
- 2021-07-19
Source: ClinicalTrials.gov record NCT04966975. Inclusion in this directory is not an endorsement.